Tag: drug development
Tufts study prices agentic AI monitoring at $21M per trial program
A Tufts CSDD analysis values Medable's AI clinical monitoring agent at up to $21M per drug program with 82x ROI…
Anthropic’s Claude takes on trial enrollment delays in ICON pact
CRO giant ICON will weave Anthropic's Claude into site selection, feasibility and enrollment monitoring across its agentic Orbis platform.
QuantHealth banks $45M to simulate trials before enrollment
Israeli startup QuantHealth raises $45M to scale AI-powered clinical trial simulations.
AstraZeneca taps AI to de-risk late-stage trials and speed up filings
AstraZeneca CEO Pascal Soriot said the company is using AI to de-risk late-stage clinical trials and accelerate regulatory submissions.
Over 173 AI-designed drugs now in trials as FDA decision nears
More than 173 AI-originated drug programs are in clinical development as of early 2026, with the first potential FDA approval…
AI-powered biosimulation shakes up animal testing in drug development
Nature Biotechnology reports that FDA's push to reduce animal testing has fueled a boom in AI biosimulation and digital twin…
Insilico and SK Biopharm ink $2.5 billion AI drug discovery deal
The partnership targets neuroimmune and CNS disorders using Insilico's Pharma.AI engine, with $18 million in upfront payments and milestone-based upside.
Bigger AI models don’t always win in drug metabolism prediction
The OpenADMET challenge found that smaller, specialized models matched or beat large foundation models at predicting how the body processes…